轴性脊柱关节炎患者5年随访中性生活质量未恶化但共病比例增加
该研究随访245例轴性脊柱关节炎(axSpA)门诊患者(男168例、女77例,基线平均年龄46岁、平均病程11.9年),评估5年间性生活质量(SQOL)变化。结果显示SQOL基本无变化,尽管心血管、内分泌及胃肠道等共病比例显著增加;仅基线每周锻炼不足1小时者(P=0.048)及65岁以上患者SQOL下降。疾病症状总体减轻,生物制剂使用增多可能有助于这一良好结局。
要点
- 5年随访中axSpA患者SQOL基本稳定,但共病比例显著增加
- 基线每周锻炼不足1小时者5年后SQOL下降(P=0.048)
- 疾病症状总体减轻,生物制剂使用增加可能贡献良好结局
核心结论
- axSpA患者5年随访中SQOL无统计学显著变化,尽管共病显著增加,疾病症状总体减轻提示疾病控制改善。
研究设计与样本
- 单中心门诊axSpA患者队列,基线及5年随访收集人口学、疾病相关、治疗及SQOL数据,SQOL采用SQOL-Female(SQOL-F)问卷评估。
- 共纳入245例axSpA患者(男168例、女77例),基线平均年龄46岁、平均病程11.9年。
- 统计分析采用McNemar检验、配对t检验及多元回归分析。
主要发现
- 与基线相比,5年随访时患者CRP更低、Maastricht强直性脊柱炎附着点炎评分更低、BASFI评分更低、吸烟更少,接受生物制剂改善病情抗风湿药(bDMARDs)治疗的患者显著增多。
- 5年随访时SQOL基本无变化,但心血管、内分泌及胃肠道疾病等共病比例显著增加。
- 仅基线每周锻炼不足1小时者(P=0.048)及65岁以上患者5年后SQOL下降。
临床怎么用
- 对axSpA患者长期随访应同时关注共病筛查与性生活质量评估,尤其对锻炼不足及高龄患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore patient perception of sexual quality of life (SQOL), an important category of QOL, in male and female patients with axial SpA (axSpA) after a 5 year follow-up. METHODS: A broad spectrum of demographic, disease-related, treatment and SQOL data was collected at baseline and at the 5 year follow-up. SQOL was assessed by the SQOL-Female (SQOL-F) questionnaire. For statistical analysis, McNemar's tests, paired t-tests and multiple regression analyses were applied. RESULTS: A total of 245 axSpA patients (168 men and 77 women) from outpatient clinics were examined (mean age 46 years, mean disease duration 11.9 years at baseline). Compared with baseline, the patients had lower CRP, lower Maastricht Ankylosing Spondylitis Enthesitis Scores, lower BASFI scores, less use of smoking and significantly more patients were treated with biologic DMARDs at the 5 year follow-up. Patient perception of SQOL was basically unchanged at the 5 year follow-up despite a significantly increased proportion of comorbidities, including cardiovascular, endocrine and gastrointestinal disease. A decrease in SQOL after 5 years was observed only in patients exercising <1 h/week at baseline (P = 0.048) and in patients >65 years old. CONCLUSION: In our axSpA patients, no statistically significant changes in SQOL were observed over 5 years, despite a significant increase in comorbidities. Overall disease symptoms decreased, indicating better disease control. Increased use of biologic drugs at the 5 year follow-up may have contributed to this favourable outcome.
引用
- Berg KH, Rohde G, Pripp A, et al. Increased proportion of comorbidities but no deterioration of sexual quality of life during a 5-year follow-up in patients with axial spondyloarthritis in the biologic treatment era. Rheumatology (Oxford). 2021. PMID: 33410472. doi:10.1093/rheumatology/keaa887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。